Movfor
Indicated to address acute viral replication to manage mild-to-moderate infections and alleviate respiratory progression risk.
- Category
- Antivirals
- Active ingredient
- Molnupiravir
- Route
- Oral use
- Form
- Capsule
- Strengths
- 200mg
Prescription and consultation requirements for Movfor vary by destination and are determined by the fulfilment partner.
Movfor details
- Condition
- Coronavirus Disease 2019 (covid-19)
- Alternative names
- molnupiravir
- Therapeutic class
- Nucleoside Analog Antiviral
- Pharmacological class
- Antiviral Agent
- Contraindications
- pregnancy; hypersensitivity to molnupiravir
- Minor side effects
- diarrhoea; nausea; dizziness
- Moderate side effects
- headache; rash; vomiting
- Serious side effects
- anaphylaxis, requires immediate medical attention
- Dosage forms
- Capsule
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Hetero Healthcare
- Onset Time
- 24–48 hours
- Duration
- 12 hours
- Storage instructions
- Store below 25°C.
- Age restrictions
- Approved for adults over eighteen years.
Patient summary
indicated to address acute viral replication to manage mild-to-moderate infections and alleviate respiratory progression risk.
Mechanism of action
Incorporates into viral RNA, causing widespread replication errors that halt viral replication in tissues.
Pregnancy and breastfeeding
TGA Category D: High risk of fetal toxicity. Strictly contraindicated in pregnancy. Breastfeeding: Avoid.